KR102315528B1 - 암 치료 - Google Patents

암 치료 Download PDF

Info

Publication number
KR102315528B1
KR102315528B1 KR1020217002758A KR20217002758A KR102315528B1 KR 102315528 B1 KR102315528 B1 KR 102315528B1 KR 1020217002758 A KR1020217002758 A KR 1020217002758A KR 20217002758 A KR20217002758 A KR 20217002758A KR 102315528 B1 KR102315528 B1 KR 102315528B1
Authority
KR
South Korea
Prior art keywords
cancer
aurka
tsa
treatment
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020217002758A
Other languages
English (en)
Korean (ko)
Other versions
KR20210013343A (ko
Inventor
미하엘 에이치. 폴리메로포울로스
루이스 윌리엄 리카멜레
크리스티안 라베단
Original Assignee
반다 파마슈티칼즈, 인코퍼레이티드.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 반다 파마슈티칼즈, 인코퍼레이티드. filed Critical 반다 파마슈티칼즈, 인코퍼레이티드.
Priority to KR1020217033186A priority Critical patent/KR20210127821A/ko
Publication of KR20210013343A publication Critical patent/KR20210013343A/ko
Application granted granted Critical
Publication of KR102315528B1 publication Critical patent/KR102315528B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020217002758A 2013-08-22 2014-08-22 암 치료 Active KR102315528B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020217033186A KR20210127821A (ko) 2013-08-22 2014-08-22 암 치료

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361869039P 2013-08-22 2013-08-22
US61/869,039 2013-08-22
KR1020177032020A KR20170126018A (ko) 2013-08-22 2014-08-22 암 치료
PCT/US2014/052209 WO2015027121A2 (en) 2013-08-22 2014-08-22 Cancer treatment

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020177032020A Division KR20170126018A (ko) 2013-08-22 2014-08-22 암 치료

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020217033186A Division KR20210127821A (ko) 2013-08-22 2014-08-22 암 치료

Publications (2)

Publication Number Publication Date
KR20210013343A KR20210013343A (ko) 2021-02-03
KR102315528B1 true KR102315528B1 (ko) 2021-10-21

Family

ID=51794948

Family Applications (5)

Application Number Title Priority Date Filing Date
KR1020217002758A Active KR102315528B1 (ko) 2013-08-22 2014-08-22 암 치료
KR1020237010047A Abandoned KR20230047203A (ko) 2013-08-22 2014-08-22 암 치료
KR1020177032020A Ceased KR20170126018A (ko) 2013-08-22 2014-08-22 암 치료
KR1020217033186A Ceased KR20210127821A (ko) 2013-08-22 2014-08-22 암 치료
KR1020167004630A Ceased KR20160033779A (ko) 2013-08-22 2014-08-22 암 치료

Family Applications After (4)

Application Number Title Priority Date Filing Date
KR1020237010047A Abandoned KR20230047203A (ko) 2013-08-22 2014-08-22 암 치료
KR1020177032020A Ceased KR20170126018A (ko) 2013-08-22 2014-08-22 암 치료
KR1020217033186A Ceased KR20210127821A (ko) 2013-08-22 2014-08-22 암 치료
KR1020167004630A Ceased KR20160033779A (ko) 2013-08-22 2014-08-22 암 치료

Country Status (12)

Country Link
US (5) US20160199323A1 (enExample)
EP (2) EP3036007B1 (enExample)
JP (4) JP2016528297A (enExample)
KR (5) KR102315528B1 (enExample)
CN (2) CN110585184A (enExample)
AU (4) AU2014308700A1 (enExample)
CA (1) CA2921036A1 (enExample)
CL (1) CL2016000397A1 (enExample)
EA (1) EA037667B1 (enExample)
ES (1) ES2755983T3 (enExample)
MX (1) MX381429B (enExample)
WO (1) WO2015027121A2 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA037638B1 (ru) * 2013-08-22 2021-04-23 Ванда Фармасьютикалз Инк. Лечение множественной миеломы
KR102315528B1 (ko) * 2013-08-22 2021-10-21 반다 파마슈티칼즈, 인코퍼레이티드. 암 치료
WO2021016203A1 (en) * 2019-07-19 2021-01-28 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Pdlim2 as a biomarker for cancer and as an anti-cancer treatment target
US20250161242A1 (en) * 2022-03-01 2025-05-22 Vanda Pharmaceuticals Inc. Trichostatin a (tsa) sensitivity in the treatment of tumors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020183388A1 (en) 2001-02-01 2002-12-05 Gudas Lorraine J. Use of retinoids plus histone deacetylase inhibitors to inhibit the growth of solid tumors

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4218478A (en) * 1979-01-05 1980-08-19 Ruiko Oiwa Trichostatin as an antiprotozoal agent
CA1265431A (en) 1985-01-08 1990-02-06 Roderick John Macdonald Electrode device for flare stack ignitor
JPS61176523A (ja) 1985-01-30 1986-08-08 Teruhiko Beppu 制癌剤
DK2238982T3 (da) * 2003-06-27 2013-01-28 Astellas Pharma Inc Terapeutisk middel til blødt væv-sarcom
DK2537942T3 (en) 2004-05-21 2015-12-14 Trustees Of The University Of Arkansas System Board Of Use of genudtryksprofilering to predict survival in cancer patients
GB0519405D0 (en) 2005-09-23 2005-11-02 Univ Aberdeen Cancer therapy prognosis and target
WO2007067516A2 (en) * 2005-12-06 2007-06-14 Duke University Multiple myeloma
CA2652888A1 (en) 2006-05-26 2007-12-06 Celgene Corporation Methods and compositions using immunomodulatory compounds in combination therapy
CA2574531C (en) * 2007-01-19 2016-10-25 The University Of British Columbia Hat acetylation promoters and uses of compositions thereof in promoting immunogenicity
EP2356255A2 (en) 2008-12-05 2011-08-17 The Institute of Cancer Research : The Royal Cancer Hospital Methods for determining a prognosis in multiple myeloma
US20120107304A1 (en) 2010-04-27 2012-05-03 Boehringer Ingelheim International Gmbh Combination therapy in treatment of oncological and fibrotic diseases
US9670549B2 (en) * 2011-11-10 2017-06-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Gene expression signatures of neoplasm responsiveness to therapy
EP2602330A1 (en) 2011-12-07 2013-06-12 Palacky University, Olomouc Method of determination of cancer cell drug sensitivity towards Aurora kinase inhibitors and overcoming their resistance
WO2013184572A1 (en) * 2012-06-04 2013-12-12 Pharmacyclics, Inc. Crystalline forms of a bruton's tyrosine kinase inhibitor
EA037638B1 (ru) 2013-08-22 2021-04-23 Ванда Фармасьютикалз Инк. Лечение множественной миеломы
KR102315528B1 (ko) * 2013-08-22 2021-10-21 반다 파마슈티칼즈, 인코퍼레이티드. 암 치료
DE102014117278A1 (de) 2014-11-25 2016-05-25 Krones Ag Hubeinheit zum Anheben und Absenken eines Behälters in einer Behälterbehandlungsanlage

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020183388A1 (en) 2001-02-01 2002-12-05 Gudas Lorraine J. Use of retinoids plus histone deacetylase inhibitors to inhibit the growth of solid tumors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Cancer Biology & Therapy. 7(9), 제1388-1397쪽(2008.09.)
Clinical Cancer Research. 7, 제971-976쪽(2001.04.)

Also Published As

Publication number Publication date
EA037667B1 (ru) 2021-04-28
AU2021261882B2 (en) 2022-04-14
MX2016002307A (es) 2016-06-15
US20190211107A1 (en) 2019-07-11
US11078289B2 (en) 2021-08-03
EP3036007B1 (en) 2019-10-09
US20210324093A1 (en) 2021-10-21
JP2023088996A (ja) 2023-06-27
US20230257471A1 (en) 2023-08-17
US12590162B2 (en) 2026-03-31
ES2755983T3 (es) 2020-04-24
KR20170126018A (ko) 2017-11-15
WO2015027121A2 (en) 2015-02-26
AU2022202183A1 (en) 2022-04-21
US20180256522A1 (en) 2018-09-13
EP3036007A2 (en) 2016-06-29
CN110585184A (zh) 2019-12-20
US10265282B2 (en) 2019-04-23
CL2016000397A1 (es) 2017-03-17
US11667718B2 (en) 2023-06-06
AU2014308700A1 (en) 2016-02-25
AU2019261718A1 (en) 2019-11-28
JP2021105005A (ja) 2021-07-26
AU2021261882A1 (en) 2021-12-02
WO2015027121A3 (en) 2015-05-14
CN105579101A (zh) 2016-05-11
JP2019167351A (ja) 2019-10-03
MX381429B (es) 2025-03-12
KR20230047203A (ko) 2023-04-06
AU2022202183B2 (en) 2023-09-28
KR20210013343A (ko) 2021-02-03
EA201690445A1 (ru) 2016-06-30
JP2016528297A (ja) 2016-09-15
KR20160033779A (ko) 2016-03-28
US20160199323A1 (en) 2016-07-14
KR20210127821A (ko) 2021-10-22
CA2921036A1 (en) 2015-02-26
EP3616754A1 (en) 2020-03-04
NZ716668A (en) 2021-02-26

Similar Documents

Publication Publication Date Title
AU2022202183B2 (en) Cancer treatment
Cao et al. HDAC5–LSD1 axis regulates antineoplastic effect of natural HDAC inhibitor sulforaphane in human breast cancer cells
JP2011525174A5 (enExample)
US20200009087A1 (en) Multiple myeloma treatment
NZ716668B2 (en) Cancer treatment
HK1226349A1 (en) Cancer treatment
HK1226349B (en) Cancer treatment
Jaafari Targeting Histone Modifications in Colorectal Cancer: Therapeutic Potential of Epigenetic Modifiers on Acetylation, Methylation and Phosphorylation
JP2025523114A (ja) Ａｔリッチ相互作用ドメイン含有タンパク質１ａ（ａｒｉｄ１ａ）突然変異癌を処置するためのｅｚｈ２阻害療法
Sredni et al. ATRT-04. A FUNCTIONAL SCREENING OF THE KINOME IDENTIFIES THE POLO-LIKE KINASE 4 (PLK4) AS A POTENTIAL THERAPEUTIC TARGET FOR ATYPICAL TERATOID/RHABDOID TUMORS (AT/RT), AND POSSIBLY, OTHER EMBRYONAL TUMORS OF THE BRAIN
TW201021801A (en) A pharmaceutical composition for the treatment of cancers
HK40004751A (en) Compositions containing decitabine, 5azacytidine and tetrahydrouridine and uses thereof

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 5